Prenatal exposure to trans fatty acids and head growth in fetal life and childhood: triangulating confounder-adjustment and instrumental variable approaches

Runyu Zou1,2,3 · Jeremy A. Labrecque4 · Sonja A. Swanson4,5 · Eric A. P. Steegers6 · Tonya White1,7,8 · Hanan El Marroun1,9 · Henning Tiemeier1,10

Received: 1 March 2022 / Accepted: 26 August 2022 / Published online: 15 September 2022
© The Author(s) 2022

Abstract
Dietary trans fatty acids (TFAs) are primarily industrially produced and remain abundant in processed food, particularly in low- and middle-income countries. Although TFAs are a cause of adverse cardiometabolic outcomes, little is known about exposure to TFAs in relation to brain development. We aimed to investigate the effect of maternal TFA concentration during pregnancy on offspring head growth in utero and during childhood. In a prospective population-based study in Rotterdam, the Netherlands, with 6900 mother–child dyads, maternal plasma TFA concentration was assessed using gas chromatography in mid-gestation. Offspring head circumference (HC) was measured in the second and third trimesters using ultrasonography; childhood brain morphology was assessed using magnetic resonance imaging at age 10 years. We performed regression analyses adjusting for sociodemographic and lifestyle confounders and instrumental variable (IV) analyses. Our IV analysis leveraged a national policy change that led to a substantial reduction in TFA and occurred mid-recruitment. After adjusting for covariates, maternal TFA concentration during pregnancy was inversely related to fetal HC in the third trimester (mean difference per 1% wt:wt increase: −0.33, 95% CI −0.51, −0.15, cm) and to fetal HC growth from the second to the third trimester (−0.04, 95% CI −0.06, −0.02, cm/week). Consistent findings were obtained with IV analyses, strengthening a causal interpretation. Association between prenatal TFA exposure and HC in the second trimester or global brain volume at age 10 years was inconclusive. Our findings are of important public health relevance as TFA levels in food remain high in many countries.

Keywords Trans fatty acids · Pregnancy · Head · Regression analysis · Instrumental variable
Introduction

Trans fatty acids (TFAs) are unsaturated fatty acids with at least one carbon–carbon double bond in the trans configuration. The major dietary TFAs are industrially produced to bring plasticity as well as emulsion stability to shortenings and enhance the palatability of baked goods and sweets [1]. Consumption of TFAs can be harmful for human health. Despite the well-documented relations between TFA intake and cardiometabolic consequences such as coronary heart disease and diabetes [2], little evidence has linked TFAs to neurodevelopmental outcomes.

The fetal period is critical for the development of brain structure and functioning, and the fetal brain is vulnerable to environmental adversities [3]. As potential nutritional adversities, TFAs accumulate in the human placenta during pregnancy, and are transported to the fetus in amounts that depend on maternal dietary intake [4]. Higher umbilical TFA levels were associated with a less optimal neurologic status as assessed by a neurological examination in children aged 18 months [5], suggesting that prenatal exposure to TFAs may impact neurodevelopment.

Head circumference (HC) can serve as a proxy for fetal brain development, because the cranial capacity corresponds to brain growth in early life [6]. Moreover, a slower HC growth in utero and smaller HC at birth are related to worse cognitive performance in childhood [7, 8]. In a Dutch cohort that included women in 2008–2009, the researchers reported no association between maternal or umbilical plasma t18:1 concentration and HC at birth [9]. To the best of our knowledge, the association between prenatal TFAs exposure and head size has not been examined using repeated measures.

Most countries rely on food producers to voluntarily reduce the content of industrial TFAs in food, and only a few European Union countries such as Denmark and Iceland have introduced legislative limits. In the Netherlands, large food producers decided to eliminate TFAs from retail products since early 1990s, and by 1996 most retail margarines contained only trace amounts of TFAs. However, fast foods and baked goods remained as the two major sources of TFAs and an important part of the Dutch diet [10]. Starting in 2003, the Margarine, Fats and Oils Product Board (Dutch abbreviation: MVO) initiated the Responsible Fatty Acid Composition Taskforce to further reduce TFA content in Dutch food. This has led to substantial reduction in TFA composition of various materials and products in the Netherlands from 2003 onwards (see Figure S1) [11], and corresponding reduction in TFA intake in the Dutch population has been documented [12].

We aimed to examine the effect of prenatal exposure to TFAs on head growth in fetal life and childhood. We used two complementary methods for effect estimation: regression analysis adjusting for measured confounders, and instrumental variable (IV) analysis. As a clear decline in maternal gestational plasma TFA concentration over the period of recruitment was evident in the current cohort [13], we proposed the calendar time of maternal TFAs assessment as an IV for the relation between maternal TFA status during pregnancy and child head measures. Because confounding bias is a major concern in observational nutrition studies, using these approaches together allows us to better support any causal inferences by triangulating approaches that rest upon different assumptions about confounding. We hypothesized that exposure to higher TFA levels was associated with suboptimal head growth characterized by a smaller HC and lower HC growth rate in fetal life, and lower global brain volume in childhood.

Methods

Setting and participants

This study was embedded in the population-based Generation R cohort. Pregnant women with an expected delivery date between April 2002 and January 2006 in Rotterdam were eligible [14]. The Generation R Study was approved by the Medical Ethics Committee of the Erasmus Medical Center, and written informed consent was obtained from adult participants.

A total of 8633 live singletons were born to women recruited in pregnancy. Among these children, 1710 were excluded due to missing data on maternal plasma TFA concentration during pregnancy. After further exclusion of those without ultrasound data on HC in the second or third trimester, 6900 children constituted the study population. Of these, 2933 children underwent a structural brain magnetic resonance imaging (MRI) session at age 9–11 years [15], and 2354 had usable data after quality control (see Figure S2 for the flow-chart).

Maternal TFA concentration during pregnancy

As previously described [16], maternal plasma fatty acids concentrations were assessed in mid-gestation (mean 20.6 weeks, SD = 1.1) using gas chromatography. The concentrations of individual fatty acids are expressed as weight percentage (%, wt:wt) of all glycerophospholipid fatty acids detected with a chain length between 14 and 22 carbon atoms. For the current study, total TFA concentration was calculated by summing the concentrations of t16:1, t18:1, and t18:2 isomers. In our sample, the interquartile range (IQR) of total TFA concentration was 0.27–0.41%, and the t18:1 isomer (IQR 0.16–0.28%) accounted for the majority...
Prenatal exposure to trans fatty acids and head growth in fetal life and childhood: triangulating…

Head growth in fetal life and childhood

Fetal HC was measured with ultrasound during each trimester of pregnancy by technicians at the Generation R Study research center [14]. First trimester ultrasounds were used for pregnancy dating. In our study population, fetal HC data were available in 6792 children in the second trimester (mean = 20.6 weeks, SD = 1.2), and 6625 children in the third trimester (mean = 30.4 weeks, SD = 1.1). The intra- and inter-observer correlation coefficients for fetal HC were 0.995 and 0.988, suggesting excellent reliability. In addition, we calculated fetal HC growth rate (in cm/week) from the second to third trimester as the difference between HC divided by the difference in gestational age in 6517 children. HC at birth measured using standardized procedures was available in 3752 children [17].

Brain morphology in childhood was assessed using MRI at age 9–11 years. All images were acquired on a 3-Tesla GE Discovery MR750w MRI System (General Electric, Milwaukee, WI, USA) scanner using an 8-channel head coil. High-resolution T1-weighted sequences were obtained using a 3D coronal inversion recovery fast spoiled gradient recalled (IR-FSPGR, BRAVO) sequence with 1-mm isotropic resolution, and images were rated for quality control both during and after the MRI acquisition [15]. Volumetric segmentation and cortical reconstruction were performed with FreeSurfer v.6.0.0 (http://surfer.nmr.mgh.harvard.edu/), and the standard reconstruction stream was applied. The quality of FreeSurfer output was visually inspected, and data with insufficient quality were eliminated. For the current study, total brain volume, and volumes of cortical gray matter and cerebral white matter were used to quantify global brain size.

Covariates

We included the following maternal and child characteristics as covariates based on prior literature [13, 18]: child sex and (gestational) age at head assessment, maternal ethnicity, age at enrollment, pre-pregnancy body mass index (BMI), psychopathology, marital status, parity, educational level, total energy intake, diet quality, smoking and alcohol use during pregnancy, and family income. Crown-rump length or bi-parietal diameter was used to determine gestational age. Maternal psychopathology was assessed using the Brief Symptom Inventory (scores range from 0 to 4, with higher scores indicating more clinically relevant psychological symptoms) [19]. Maternal diet quality was assessed in early pregnancy using a semi-quantitative 293-item food frequency questionnaire and quantified by an overall score ranging from 0 to 15, with higher score reflecting better adherence to Dutch dietary guidelines [20].

Additional variables

Information on calendar time of maternal TFA assessment during pregnancy was used as an IV for the IV analysis. The recruitment of pregnant women approximately concurred with the initiative on TFAs reduction (see Fig. 1 and Figure S1).

Given the evidence suggesting a relation between prenatal HC and childhood cognitive development [7, 8], child non-verbal IQ assessed at age 5–9 (mean = 6.2) years was used in a secondary analysis [21]. We examined the association of HC in utero with cognitive abilities in childhood in our sample to highlight the clinical implications of our findings.

Statistical analysis

For descriptive purposes, continuous variables were presented as mean (SD) and categorical variables as number (%). In a non-response analysis, we describe the characteristics of children with and without MRI data at 9–11 years,

Fig. 1 Maternal trans fatty acid concentration during pregnancy per calendar time of assessment. Maternal TFA concentration (% wt:wt, mean ± se) per calendar time of TFA assessment. Maternal TFA concentration was assessed in the plasma at 20.6 (1.1) weeks of gestation. The Dutch initiative to further reduce TFA content in food took effect in 2003. Abbreviation: TFA, Trans fatty acid.
using analysis of variance (ANOVA) or Wilcoxon test for continuous variables, and chi-square tests for categorical variables.

We investigated the association of maternal TFA concentration with HC in second and third trimesters, fetal HC growth rate, and global brain volume (i.e., total brain volume, cortical gray matter volume, and cerebral white matter volume) at age 9–11 years using linear regression. We also examined maternal TFA concentration in relation to HC at birth in a supplementary analysis. These regression analyses were performed using multi-stage models with different levels of confounder adjustment, to explore how adjustment for measured confounding affects estimates. In the initial model, only child sex and (gestational) age at outcome assessment were adjusted for. Using a change-in-estimate criterion of 5% [22], maternal ethnicity, age at enrollment, educational level, diet quality, smoking during pregnancy, and family income were selected from the covariate pool as confounders and were additionally adjusted for in a second model. In a third model, we additionally corrected for concentrations of maternal essential fatty acids (EFAs, i.e., α-linoleic acid and linoleic acid) and long-chain polyunsaturated fatty acids (LC-PUFAs), because they can be either confounders (i.e., reductions of TFA may increase PUFAs in body fat composition) or intermediates (i.e., TFA may interfere with EFAs and reduce the synthesis of LC-PUFAs) [23–25]. Further, models with MRI measures were weighted by inverse probability weights to account for attrition (see supplementary methods for details). We examined non-linear relations by comparing the linear model and the model including splines using likelihood ratio test.

To explore implications on long-term neurocognitive development, we investigated prenatal exposure to TFA, and HC and HC growth rate in utero in relation to nonverbal IQ at age 6 years in a secondary analysis.

Next, for head outcomes that were substantially associated with maternal TFA concentration using confounder-adjustment approaches, we performed an IV analysis using two-stage least squares (TSLS) estimation [26]. Calendar time of maternal TFA assessment was proposed as the IV given the initiative to reduce food TFA content in the Netherlands since 2003. In addition, we assessed the basic assumptions of IV analysis (see supplementary methods for details) to evaluate whether calendar time of maternal TFA assessment could be utilized as an IV. For the ‘relevance’ assumption, we examined the association between calendar time of maternal TFA assessment and maternal TFA concentration, both with and without adjusting for covariates. In addition, we performed an F-test on the instrument in the first stage of the TSLS regression. Since the ‘exclusion restriction’ and ‘exchangeability’ assumptions cannot be verified, we explored our rich observed data in ways that might falsify these assumptions. These analyses were performed to minimize the risk that a covariate with a similar time trend as maternal TFA concentration underlies the relation between calendar time of maternal TFA assessment and child head measures. First, we related calendar time of maternal TFA assessment to each covariate using separate linear or logistic regression model, and covariates that did not vary by calendar time of maternal TFA assessment were excluded. Second, the mean ± standard error (se) of each remaining covariate over calendar time of maternal TFA assessment was plotted to inspect time trends. In the primary IV analysis, we adjusted for no covariates, and the sandwich estimator was used because it is robust to heteroscedastic errors. In the secondary analysis, we conducted two TSLS regressions to rule out bias caused by any measured nuisance variables: first, we adjusted for covariates with a potential monotonic time trend; second, we adjusted for all covariates regardless their variation over calendar time. Since maternal TFA concentration was the dependent variable in the first-stage model of the IV analysis, we log-transformed the raw values to obtain a normal distribution. Finally, because we are interested in seeing how the IV analysis results complement the confounding-adjustment regression results, we interpret our IV analyses as primarily testing a causal null hypothesis [27].

We performed two sensitivity analyses to test the robustness of our findings. First, we re-ran the analysis in participants of Dutch national origin only. Second, we examined the trans 18:1 fatty acid, the primary TFA isomer, as exposure of interest.

Missing data on covariates were accounted for by multiple imputation. We generated 20 imputed datasets with 20 iterations, and report pooled results. Statistical significance was set as $\alpha < 0.05$ (two-sided), and a false discovery rate (FDR) correction was performed in primary analyses [28]. All statistical analyses were performed using R version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria), including the ‘ivpack’ package for IV analysis.

**Results**

**Descriptive**

Table 1 shows the characteristics of the participating mother–child dyads. Enrolled at an average age of 29.8 years, nearly half of the mothers were of Dutch national origin, and the majority (87.6%) had completed secondary education or above. Compared to children with MRI data, those without MRI data were born to younger and less highly educated women, more likely had parents with less income, and were exposed to higher maternal TFA concentration during pregnancy (see Table S1).
Prenatal exposure to trans fatty acids and head growth in fetal life and childhood: triangulating…

The mean difference in HC in the second trimester per 1%, wt:wt increase in maternal TFAs was 0.07 (95% CI −0.05, 0.19) cm, with similar results for different levels of confounding adjustment (Table 2). However, there was a strong difference in the third trimester, namely a 1%, wt:wt higher TFA concentration of the mother corresponded to 0.33 (95% CI 0.51, 0.15) cm lower HC of the fetus. Higher maternal TFA levels during pregnancy were also related to lower HC growth rate, namely per 1%, wt:wt increase in TFA concentration of the mother corresponded to 0.04 (95% CI: 0.06, 0.02) cm/week slower HC growth of the fetus. Both associations survived FDR correction. Consistent findings were obtained using log-transformed or absolute concentration of maternal TFA (see Table S2-S3). Despite a positive trend, the association of prenatal exposure to TFA with HC at birth was not definite after full adjustment for covariates (B = 0.4, 95% CI −0.04, 0.8, cm). We found no evidence for non-linear relations (see Table S4).

Prenatal exposure to TFA and MRI measures at age ten years

In children with MRI assessments at age 10 years, after full adjustment for covariates, we observed an increase in child total brain volume per 1%, wt:wt higher maternal TFA concentration (mean = 7.8 cm³, 95% CI −24.7, 40.3, not weighted by inverse probability; and 21.5 cm³, 95% CI −13.2, 56.3, weighted by inverse probability). However, the wide confidence intervals suggest these are inconclusive associations. Similar findings were obtained when relating maternal TFA concentration during pregnancy to cortical gray or cerebral white matter volume of the child (see Table 3).

IV analysis

The calendar time of maternal TFA assessment ranged from January 2002 to September 2005. Figure 1 visualizes the change of maternal TFA concentration (mean ± se) over time. There was an inverse, overall monotonic relation between calendar time of TFA assessment and TFA concentration, except in the first few months (see Figure S3 for logarithmically transformed values).

The calendar time of maternal TFA assessment was inversely associated with maternal TFA concentration (mean reduction in %, wt:wt per month, without adjustment for covariates: −0.0108, 95% CI −0.0115, −0.0101; after adjustment for covariates: −0.0104, 95% CI −0.0111, −0.0097), and the heteroskedasticity-robust F-statistic for calendar time of TFA assessment in the covariate-adjusted model was 971.8 (p < 0.001), supporting the ‘relevance’ assumption. Next, we examined potential violation of the ‘exclusion restriction’ and ‘exchangeability’ assumptions; child sex and gestational age at ultrasound, maternal ethnicity, and family income were not predicted by calendar time of TFA assessment. Figure S4 shows variations of maternal age at enrollment, educational level, diet quality, and smoking during pregnancy over calendar time of...
maternal TFA assessment, with the most plausible monotonic time trend observed in diet quality. Table 4 shows the results of IV analysis. Higher maternal TFA concentration during pregnancy was associated with smaller fetal HC in the third trimester and lower HC growth rate from the second to the third trimester in the unadjusted model (Model 1). Consistent findings were obtained in analyses adjusting for covariates with time variations only (Model 2) or all covariates (Model 3), suggesting robust findings.

Analyses in participants of Dutch national origin or examining the trans 18:1 fatty acid isomer yielded results similar to the primary analyses (see Table S5-S8, Figure S5-S6).

### TFA concentration during pregnancy and HC in fetal life in relation to nonverbal IQ in childhood

As shown in Table S9, we observed no association between prenatal TFA exposure and nonverbal IQ at age 6 years after full adjustment for covariates. However, both HC in the third trimester and HC growth rate between the second and third trimesters were positively related to nonverbal IQ at year 6 years.

---

**Table 2** Maternal trans fatty acid concentration during pregnancy in relation to fetal head circumference and head circumference growth

| Maternal TFA concentration | Fetal HC at single assessments<sup>a</sup> | Fetal HC growth rate across assessments<sup>b</sup> (n = 6517) |
|----------------------------|------------------------------------------|--------------------------------------------------|
|                            | Second trimester (n = 6792) | Third trimester (n = 6625) |                            |
|                            | B 95% CI  p-value | B 95% CI  p-value | B 95% CI  p-value |
| Model 1                   | 0.13 0.01, 0.24 0.03 | −0.26 −0.43, −0.08 0.004 | −0.04 −0.05, −0.02 <0.001 |
| Model 2                   | 0.12 0.004, 0.24 0.04 | −0.30 −0.47, −0.12 <0.001 | −0.04 −0.06, −0.02 <0.001 |
| Model 3                   | 0.07 −0.05, 0.19 0.24 | −0.33 −0.51, −0.15 <0.001<sup>*</sup> | −0.04 −0.06, −0.02 <0.001<sup>*</sup> |

**TFA** Trans fatty acid, **HC** Head circumference

<sup>a</sup>B’s represent difference in fetal HC (cm) per 1%, wt:wt increase in maternal TFA concentration. Model 1 was adjusted for child sex and gestational age at HC assessment; Model 2 was additionally adjusted for maternal ethnicity, age at enrollment, educational level, diet quality, smoking during pregnancy, and family income; Model 3 was additionally adjusted for maternal concentrations of essential fatty acids and long-chain polyunsaturated fatty acids.

<sup>b</sup>B’s represent difference in fetal HC growth rate (cm/week) per 1%, wt:wt increase in maternal TFA concentration. Model 1 was adjusted for child sex. Model 2 was additionally adjusted for maternal ethnicity, age at enrollment, educational level, diet quality, smoking during pregnancy, and family income. Model 3 was additionally adjusted for maternal concentrations of essential fatty acids and long-chain polyunsaturated fatty acids.

<sup>*</sup>These <i>p</i>-values survived a false discovery rate (FDR) correction for multiple comparison.

---

**Table 3** Maternal trans fatty acids concentration during pregnancy in relation to child brain volumes at age 9–11 years

| Maternal TFA concentration | Total brain volume | Cortical gray matter volume | Cerebral white matter volume |
|----------------------------|-------------------|----------------------------|-----------------------------|
|                            | B 95% CI  p-value | B 95% CI  p-value | B 95% CI  p-value |
| Without IPW                |                   |                           |                             |
| Model 1                    | 32.1 −0.8, 65.0 0.06 | 19.1 2.6, 35.6 0.02 | 9.6 5.3, 24.6 0.21 |
| Model 2                    | 7.9 −24.4, 40.1 0.63 | 6.7 −9.4, 22.8 0.41 | 2.0 13.0, 16.9 0.80 |
| Model 3                    | 7.8 −24.7, 40.3 0.64 | 6.5 −9.7, 22.8 0.43 | 2.4 12.7, 17.4 0.76 |
| With IPW                   |                   |                           |                             |
| Model 1                    | 41.9 8.5, 75.4 0.01 | 23.4 6.6, 40.2 0.006 | 14.6 0.9, 30.1 0.06 |
| Model 2                    | 21.0 −13.3, 55.3 0.23 | 13.1 −4.5, 30.6 0.14 | 8.0 7.8, 23.9 0.32 |
| Model 3                    | 21.5 −13.2, 56.3 0.22 | 13.5 −4.4, 31.3 0.14 | 8.3 7.7, 24.4 0.31 |

**TFA** Trans fatty acid, **IPW** Inverse probability weighting (used to account for attrition)

B’s represent volumetric difference (cm<sup>3</sup>) per 1%, wt:wt increase in maternal TFA concentration. Model 1 was adjusted for child sex and age at neuroimaging. Model 2 was additionally adjusted for maternal ethnicity, age at enrollment, educational level, diet quality, smoking during pregnancy, and family income. Model 3 was additionally adjusted for maternal concentrations of essential fatty acids and long-chain polyunsaturated fatty acids. The sample size for all analyses was 2354.
In this population-based study, a higher gestational TFA level was associated with a smaller fetal HC in the third trimester and lower fetal HC growth rate from the second to the third trimester. Analyses utilizing the fact that average TFA concentration in maternal plasma decreased over the years of enrollment showed consistent results. We found no clear association between prenatal exposure to TFAs and fetal HC in the second trimester or global brain volume at age 10 years.

A few studies related maternal TFAs during pregnancy to birth outcomes such as birth length and birth weight [13, 29], but the association between exposure to TFAs during pregnancy and head growth has rarely been examined. Dirix et al. [9, 30] found neither maternal plasma t18:1 content during pregnancy or at delivery, nor umbilical cord plasma t18:1 concentration was related to neonatal HC. The null association between maternal TFA concentration during pregnancy and child HC at birth was replicated in the current study. However, it is important to note that postnatal HC measurements also include skin and subcutaneous tissue. Further, the accuracy of postnatal HC is lower and influenced by the measuring tape [31].

To the best of our knowledge, there have been no studies associating prenatal TFAs exposure with sonographic HC in utero or child brain morphology.

Our study suggests that the smaller HC in the third trimester of the fetus exposed to higher maternal TFA levels during mid-pregnancy could be attributed to the slower HC growth from the second to the third trimester. This association was not accounted for by maternal EFAs or LC-PUFAs concentrations. Several other explanations are possible. First, randomized clinical trials (RCTs) and observational studies indicated that TFAs are associated with systematic inflammation, characterized by elevated C-reactive protein (CRP) and pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α) and interleukin 6 (IL-6) [32]. Smaller brains in mice offspring exposed to maternal immune activation during pregnancy have been reported [33]. Second, considerable epigenomic changes take place in the human brain during fetal brain development. Robinson et al. [34] found maternal TFAs at preconception and in pregnancy were related to hypomethylation of about 50% of CpG sites in the newborn. Similarly, high TFA doses were related to global hypomethylation in a rodent model [35].

Despite the HC differences in the third trimester, associations between prenatal exposure to TFA levels and global brain size at age 10 years were inconclusive. An absence of differences in brain size may be explained by catch-up head growth after birth, which has been reported in preterm birth and/or small-for-gestational-age term infants [36, 37]. Given the inherent brain plasticity, favorable environmental inducers such as breastfeeding and healthy diet in childhood may gradually revert the differences in brain size in the third trimester due to TFAs exposure [38]. Moreover, the sample

### Table 4

| Model | Fetal HC in the third trimestera | Fetal HC growth rate across assessmentsb |
|-------|----------------------------------|-----------------------------------------|
|       | B  | 95% CI | p-value | B  | 95% CI | p-value |
| 1     | -0.77 | -1.0, -0.51 | <0.001 | -0.11 | -0.13, -0.09 | <0.001 |
| 2     | -0.66 | -0.91, -0.40 | <0.001 | -0.10 | -0.12, -0.08 | <0.001 |
| 3     | 1.0  | -1.2, -0.79  | <0.001 | -0.11 | -0.14, -0.09 | <0.001 |

**HC** Head circumference

Instrumental variable analysis on maternal trans fatty acids concentration during pregnancy in relation to fetal HC in the third trimester (n = 6383) and HC growth across assessments in the second and third trimesters (n = 6280) was performed using two-stage least squares estimation. Calendar time of maternal trans fatty acids assessment was used as the instrumental variable. The raw values of maternal trans fatty acids concentration were log-transformed to obtain a normal distribution.

*a* B’s represent difference in fetal HC (cm) per one unit increase in natural logarithm transformed maternal trans fatty acids concentration. Model 1 was adjusted for no covariates. Model 2 was adjusted for maternal age at enrollment, educational level, diet quality, and smoking during pregnancy. Model 3 was adjusted for all covariates, including gestational age at ultrasound, child sex, maternal ethnicity, age at enrollment, educational level, diet quality, smoking during pregnancy, family income, and maternal concentrations of essential fatty acids and long-chain polyunsaturated fatty acids.

*b* B’s represent difference HC growth rate (cm/week) per one unit increase in natural logarithm transformed maternal trans fatty acids concentration. Model 1 was adjusted for no covariates. Model 2 was adjusted for maternal age at enrollment, educational level, diet quality, and smoking during pregnancy. Model 3 was adjusted for all covariates, including child sex, maternal ethnicity, age at enrollment, educational level, diet quality, smoking during pregnancy, family income, and maternal concentrations of essential fatty acids and long-chain polyunsaturated fatty acids.

### Discussion

In this population-based study, a higher gestational TFA level was associated with a smaller fetal HC in the third trimester and lower fetal HC growth rate from the second to the third trimester. Analyses utilizing the fact that average TFA concentration in maternal plasma decreased over the years of enrollment showed consistent results. We found no clear association between prenatal exposure to TFAs and fetal HC in the second trimester or global brain volume at age 10 years.

A few studies related maternal TFAs during pregnancy to birth outcomes such as birth length and birth weight [13, 29], but the association between exposure to TFAs during pregnancy and head growth has rarely been examined. Dirix et al. [9, 30] found neither maternal plasma t18:1 content during pregnancy or at delivery, nor umbilical cord plasma t18:1 concentration was related to neonatal HC. The null association between maternal TFA concentration during pregnancy and child HC at birth was replicated in the current study. However, it is important to note that postnatal HC measurements also include skin and subcutaneous tissue. Further, the accuracy of postnatal HC is lower and influenced by the measuring tape [31].

To the best of our knowledge, there have been no studies associating prenatal TFAs exposure with sonographic HC in utero or child brain morphology.

Despite the HC differences in the third trimester, associations between prenatal exposure to TFA levels and global brain size at age 10 years were inconclusive. An absence of differences in brain size may be explained by catch-up head growth after birth, which has been reported in preterm birth and/or small-for-gestational-age term infants [36, 37]. Given the inherent brain plasticity, favorable environmental inducers such as breastfeeding and healthy diet in childhood may gradually revert the differences in brain size in the third trimester due to TFAs exposure [38]. Moreover, the sample
size for the MRI analyses was roughly 1/3 of that for the HC analyses, limiting the ability to detect subtle differences.

Causal inference is challenging in most nutritional epidemiological studies using an observational design because of unmeasured or residual confounding often related to other lifestyle choices and socio-economic factors [39]. RCTs would provide rigorous evidence for causal effect estimation but are frequently not feasible or ethical to study the impact of TFAs. In observational studies, coupling confounder-adjustment analyses with IV analysis can help elucidate the effects of diet or nutrients on health because they rely on different assumptions than the no-unmeasured-confounding assumption of common observational study analyses [40]. In the current study, IV and regression analyses allowed for estimating the effect of maternal TFAs on child head measures under distinct assumptions. The agreement between the results of the regression and IV analyses strengthens the possibility that the association between TFA exposure and fetal head growth is causal [41]. This triangulation integrated results from different approaches with different possible sources of bias. Furthermore, we performed analyses adjusting for covariates in the TSLS regression to support our findings. In these analyses, even covariates with a less clear monotonic time trend were included to limit subjective confounder selection. For example, maternal smoking during pregnancy was adjusted for given the strong evidence suggesting its impact on fetal head growth [42], despite an unclear monotonic pattern of variation over calendar time.

Our findings have important public health implications, because WHO aims at global elimination of industrially produced TFAs by 2023, yet industrial TFA content in food remains high, in particular, in South Asia (e.g., India), and Eastern and South-eastern European countries [43, 44]. Statutory measures to reduce TFA intake are uncommon, even in the USA or the European Union. Moreover, even in countries that booked successes in reducing TFAs, high levels of TFA can still be found in certain foods (e.g., biscuits) [45]. Therefore, pregnant women living in countries/regions with high TFA content in food, or those with a preference for food containing high TFA levels have substantially elevated risk of exceeding TFA intake. The smaller fetal HC related to higher TFA exposure may have clinical implications. Previous studies associated lower HC in utero with suboptimal neurodevelopment such as more autistic traits and sleep problems in childhood [46, 47]. The current analyses show that children with a smaller HC in utero also had worse cognitive abilities at age 6 years. Therefore, reduction on maternal TFA intake during pregnancy likely favors offspring neurodevelopment.

Several limitations should be acknowledged. First, we did not assess maternal TFA status in early pregnancy when the basis of embryonal neurodevelopment is substantially formed. However, because the diet patterns of women is reasonably stable across pregnancy [48], maternal TFA levels in mid-gestation were likely indicative of those in the earlier stages. Second, we examined the primary TFA isomer, but were not able to examine other specific isomers, such as t9-C18:1t and t10-C18:1t. However, there is no evidence for a specific mechanism of action [49]. Third, concerns about the violation of some IV assumptions in nutritional research have been raised because nutrition is correlated with numerous other lifestyle and environmental factors [50]. In the current study, we accounted for various variables in the IV analysis, such as EFAs, LC-PUFAs, and diet quality that might index overall nutritional status. However, residual confounding by other nuisance variables, especially those with a similar time trend (e.g., specific nutrients used to replace the TFAs) that may attenuate the observed relations, could not be ruled out.

To conclude, exposure to higher TFA levels during pregnancy is related to lower HC in the third trimester and slower HC growth from the second to the third trimester. These findings further justify advocating TFAs reduction across the globe in the pursuit of optimal child development.

References

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s10654-022-00910-4.

Acknowledgements We sincerely thank the contributions of the participating children and parents, general practitioners, hospitals, midwives, and pharmacies in Rotterdam.

Funding RZ is supported by China Scholarship Council grant (201606100056); HM is supported by Stichting Volksbond Rotterdam, the Brain and Behavior Research Foundation NARSAD Young Investigator Grant (27853), and the Dutch Research Council (NWO) Aspasia Grant (015.016.056); TW is supported by the Netherlands Organization for Health Research and Development ZonMw TOP project (91211921); HT is supported by the Netherlands Organization for Health Research and Development ZonMw Vici Grant (016. VICI.170.200). This study was also supported by the European Union’s Horizon 2020 research and innovation program (733206 LifeCycle). Supercomputing resources were supported by the Netherlands Organization for Scientific Research (Exacte Wetenschappen) and SURFsara (Cartesius Computer Cluster, www.surfsara.nl).

Declarations

Competing interests The authors have no relevant financial or non-financial interests to disclose.

Ethical approval The Generation R Study was approved by the Medical Ethics Committee of the Erasmus Medical Center.

Consent to participate Written informed consent was obtained from adult participants.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Mozaffarian D, Stampfer MJ. Removing industrial trans fat from foods. BMJ. 2010;340:c1826.
2. Micha R, Mozaffarian D. Trans fatty acids: effects on metabolic syndrome, heart disease and diabetes. Nat Rev Endocrinol. 2009;5(6):335–44.
3. Schlotz W, Phillips DI. Fetal origins of mental health: evidence and mechanisms. Brain Behav Immun. 2009;23(7):905–16.
4. Innis SM. Fatty acids during pregnancy, infancy and early childhood. Atheroscler Suppl. 2006;7(2):17–20.
5. Bouwstra H, Dijck-Brouwer J, Decsi T, et al. Neurologic development at 2 years of age: INTERBIO-21st Fetal Study. Nat Med. 2009;15:75.
6. Kyriakopoulou V, Vatansever D, Davidson A, et al. Normative biometry of the fetal brain using magnetic resonance imaging. Brain Struct Funct. 2017;222(5):2295–307.
7. Veena SR, Krishnaveni GV, Wills AK, et al. Association of Birthweight and Head Circumference at Birth to Cognitive Performance in 9- to 10-Year-Old Children in South India: Prospective Birth Cohort Study. Pediatrie Res. 2010;67(4):424–9.
8. Villar J, Gunier RB, Tshivuila-Matala COO, et al. Fetal cranial growth trajectories are associated with growth and neurodevelopment at 2 years of age: INTERBIO-21st Fetal Study. Nat Med. 2021;27(4):647–52.
9. Dirix CE, Kester AD, Hornstra G. Associations between fetal birth dimensions and maternal essential and trans fatty acid contents during pregnancy and at delivery. Br J Nutr. 2009;101(3):399–407.
10. Katan MB. Regulation of trans fats: the gap, the Polder, and McDonald’s French fries. Atheroscler Suppl. 2006;7(2):63–6.
11. Task Force Verantwoorde Vetzuursamenstelling. 2015. https://mvo.nl/themas/voeding-gezondheid/taskforce-verantwoorde-vetzuursamenstelling. Accessed 12 November 2021.
12. Temme EH, Millenaar IL, Van Donkersgoed G, Westenbrink S. Impact of fatty acid food reformulations on intake of Dutch young adults. Acta Cardiol. 2011;66(6):721–8.
13. Grootendorst-van Mil NH, Tiemeier H, Steenweg-de Graaff J, Jaddoe VW, Steegers EA, Steegers-Theunissen RP. Maternal midpregnancy plasma trans 18:1 fatty acid concentrations are positively associated with risk of maternal vascular complications and child low birth weight. J Nutr. 2017;147(3):398–403.
14. Kosojman MN, Kruthof CJ, van Duijn CM, et al. The Generation R Study: design and cohort update 2017. Eur J Epidemiol. 2016;31(12):1243–64.
15. White T, Muetzel RL, El Marroun H, et al. Paediatric population neuroimaging and the Generation R Study: the second wave. Eur J Epidemiol. 2018;33(1):99–125.
16. Steenweg-de Graaff JC, Tiemeier H, Basten MG, et al. Maternal LC-PUFA status during pregnancy and child problem behavior: the Generation R Study. Pediatr Res. 2015;77(3):489–97.
17. Jaddoe VW, van Duijn CM, van der Heijden AJ, et al. The Generation R Study: design and cohort update 2010. Eur J Epidemiol. 2010;25(11):823–41.
18. Voortman T, Tielmeijer MJ, Stroobant W, et al. Plasma fatty acid patterns during pregnancy and child’s growth, body composition, and cardiometabolic health: The Generation R Study. Clin Nutr. 2018;37(3):984–92.
19. Derogatis LR. Brief Symptom Inventory. Baltimore, MD: Clinical Psychometric Research. 1975.
20. Klipstein-Grobusch K, den Breejen JH, Goldbohm RA, et al. Dietary assessment in the elderly: validation of a semi-quantitative food frequency questionnaire. Eur J Clin Nutr. 1998;52(8):588–96.
21. Cortes Hidalgo AP, Neumann A, Bakermans-Kranenburg MJ, et al. Prenatal maternal stress and child IQ. Child Dev. 2020;91(2):347–65.
22. Evans D, Chaix B, Lobbezoo T, Verger C, Flahault A. Combining directed acyclic graphs and the change-in-exitme procedure as a novel approach to adjustment-variable selection in epidemiology. BMC Med Res Methodol. 2012;12:156.
23. Kummerow FA, Zhou Q, Mahfouz MM, Smiricky MR, Grieshop CM, Schaeffler DJ. Trans fatty acids in hydrogenated fat inhibited the synthesis of the polyunsaturated fatty acids in the phospholipid of arterial cells. Life Sci. 2004;74(22):2707–23.
24. Downs SM, Thow AM, Leeder SR. The effectiveness of policies for reducing dietary trans fats: a systematic review of the evidence. Bull World Health Organ. 2013;91(4):262–9.
25. Li LJ, Wu J, Chen Z, et al. Plasma phospholipid polyunsaturated fatty acids composition in early pregnancy and fetal growth trajectories throughout pregnancy: findings from the US fetal growth studies-singletons cohort. EBioMedicine. 2022;82:104180.
26. Angrist JD, Imbens GW. Two-stage least squares estimation of average causal effects in models with variable treatment intensity. J Am Stat Assoc. 1995;90(430):431–42.
27. Swanson SA, Labrecque J, Hernán MA. Causal null hypotheses of sustained treatment strategies: What can be tested with an instrumental variable? Eur J Epidemiol. 2018;33(8):723–8.
28. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(289–300.
29. Cohen JF, Rifas-Shiman SL, Rimm EB, Oken E, Gillman MW. Maternal trans fatty acid intake and fetal growth. Am J Clin Nutr. 2011;94(5):1241–7.
30. Dirix CEH, Kester AD, Horistra G. Associations between term birth dimensions and prenatal exposure to essential and trans fatty acids. Early Hum Dev. 2009;85(8):525–30.
31. Wegryn P, Borowski D, Bomba-Oporn D, Wielgos M. Accuracy of sonographic estimation of fetal head circumference. Ultrasound Obstet Gynecol. 2011;37(6):743.
32. Wallace SK, Mozaffarian D. Trans-fatty acids and nonlipid risk factors. Curr Atheroscler Rep. 2009;11(6):423.
33. Kreitz S, Zambon A, Ronovsky M, et al. Maternal immune activation during pregnancy impacts on brain structure and function in the adult offspring. Brain Behav Immun. 2020;83:104180.
34. Robinson SL, Mumford SL, Guan W, et al. Maternal fatty acid concentrations and newborn DNA methylation. Am J Clin Nutr. 2019;111(3):613–21.
35. Flores-Sierra J, Arredondo-Guerrero M, Cervantes-Paz B, et al. The trans fatty acid elaidate affects the global DNA methylation profile of cultured cells and in vivo. Lipids Health Dis. 2016;15:75.

Prenatal exposure to trans fatty acids and head growth in fetal life and childhood: triangulating…
36. Fewtrell MS, Morley R, Abbott RA, et al. Catch-up growth in small-for-gestational-age term infants: a randomized trial. Am J Clin Nutr. 2001;74(4):516–23.
37. Ghods E, Kreissl A, Brandstetter S, Fuiko R, Widhalm K. Head circumference catch-up growth among preterm very low birth weight infants: effect on neurodevelopmental outcome. J Perinat Med. 2011;39(5):579–86.
38. Murphy T, Dias GP, Thuret S. Effects of diet on brain plasticity in animal and human studies: mind the gap. Neural Plast. 2014;2014:563160.
39. Qi L. Mendelian randomization in nutritional epidemiology. Nutr Rev. 2009;67(8):439–50.
40. Katan MB. Confounding in nutritional epidemiology; is Mendelian randomization the answer? Ned Tijdschr Geneeskd. 2020;164:D4759.
41. Matthay EC, Hagan E, Gottlieb LM, et al. Alternative causal inference methods in population health research: evaluating tradeoffs and triangulating evidence. SSM Popul Health. 2020;10:100526.
42. Brand JS, Gaillard R, West J, et al. Associations of maternal quitting, reducing, and continuing smoking during pregnancy with longitudinal fetal growth: findings from Mendelian randomization and parental negative control studies. PLoS Med. 2019;16(11):e1002972.
43. Kakde S, Bhopal RS, Bhardwaj S, Misra A. Urbanized South Asians’ susceptibility to coronary heart disease: the high-heat food preparation hypothesis. Nutrition. 2017;33:216–24.
44. Stender S. Industrially produced trans fat in popular foods in 15 countries of the former Soviet Union from 2015 to 2016: a market basket investigation. BMJ Open. 2019;9(2):e023184.
45. Wanders AJ, Zock PL, Brouwer IA. Trans fat intake and its dietary sources in general populations worldwide: a systematic Review. Nutrients. 2017;9(8):840.
46. Blanken LME, Dass A, Alvares G, et al. A prospective study of fetal head growth, autistic traits and autism spectrum disorder. Autism Res. 2018;11(4):602–12.
47. Kocervska D, Verhoeff ME, Meinderts S, et al. Prenatal and early postnatal measures of brain development and childhood sleep patterns. Pediatr Res. 2018;83(4):760–6.
48. Crozier SR, Robinson SM, Godfrey KM, Cooper C, Inskip HM. Women’s dietary patterns change little from before to during pregnancy. J Nutr. 2009;139(10):1956–63.
49. Gebauer SK, Psota TL, Kris-Etherton PM. The diversity of health effects of individual trans fatty acid isomers. Lipids. 2007;42(9):787–99.
50. Merino J, Tobias DK. The unique challenges of studying the genetics of diet and nutrition. Nat Med. 2022;28(2):221–2.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.